Report Sections

See All Reports

  • HP:0006515: Interstitial pneumonitis
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0006515: Interstitial pneumonitis

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (35)


    Name (Synonyms) Correlation
    drug3386 Tofacitinib Wiki 0.31
    drug3180 Sterile Normal Saline for Intravenous Use Wiki 0.27
    drug3710 bovhyaluronidase azoxymer Wiki 0.27
    Name (Synonyms) Correlation
    drug710 Centricyte 1000 Wiki 0.27
    drug3167 Standard treatment according to the Clinical protocols Wiki 0.27
    drug2914 SELF-BREATHE Wiki 0.27
    drug2653 Pulmonary function tests Wiki 0.27
    drug2000 Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki 0.27
    drug1642 Interferon-Alpha2B Wiki 0.27
    drug2150 Nintedanib Wiki 0.27
    drug1583 Imaging Wiki 0.27
    drug875 Convalescent Serum Wiki 0.27
    drug2655 Pulmonary ultrasound Wiki 0.27
    drug1518 Hydroxychloroquine, Clindamycin, Primaquine - high dose. Wiki 0.27
    drug1562 IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki 0.27
    drug1517 Hydroxychloroquine, Clindamycin Wiki 0.27
    drug772 Clinical, laboratory and imaging characteristics of pneumonia Wiki 0.27
    drug3797 high-titer anti-Sars-CoV-2 plasma Wiki 0.27
    drug1516 Hydroxychloroquine, Azithromycin Wiki 0.27
    drug191 Allogenic pooled olfactory mucosa-derived mesenchymal stem cells Wiki 0.27
    drug1519 Hydroxychloroquine, Clindamycin, Primaquine - low dose. Wiki 0.27
    drug1780 Liberase Enzyme (Roche) Wiki 0.27
    drug380 BRII-196 Wiki 0.27
    drug567 COVI-AMG Wiki 0.27
    drug1520 Hydroxychloroquine, Doxycycline Wiki 0.27
    drug2977 Scanning Chest X-rays and performing AI algorithms on images Wiki 0.27
    drug3930 oxygen therapy Wiki 0.19
    drug4037 survey Wiki 0.19
    drug481 Blood sampling Wiki 0.09
    drug1824 Losartan Wiki 0.09
    drug1995 Methylprednisolone Wiki 0.07
    drug2782 Remdesivir Wiki 0.05
    drug3375 Tocilizumab Wiki 0.04
    drug2448 Placebo Wiki 0.04
    drug1472 Hydroxychloroquine Wiki 0.03

    Correlated MeSH Terms (23)


    Name (Synonyms) Correlation
    D017563 Lung Diseases, Interstitial NIH 1.00
    D008171 Lung Diseases, NIH 0.34
    D001987 Bronchiectasis NIH 0.31
    Name (Synonyms) Correlation
    D011658 Pulmonary Fibrosis NIH 0.28
    D001469 Barotrauma NIH 0.27
    D011649 Pulmonary Alveolar Proteinosis NIH 0.27
    D004646 Emphysema NIH 0.27
    D017093 Liver Failure NIH 0.27
    D054990 Idiopathic Pulmonary Fibrosis NIH 0.19
    D005355 Fibrosis NIH 0.15
    D003550 Cystic Fibrosis NIH 0.15
    D000755 Anemia, Sickle Cell NIH 0.13
    D011014 Pneumonia NIH 0.13
    D011024 Pneumonia, Viral NIH 0.12
    D053717 Pneumonia, Ventilator-Associated NIH 0.09
    D004417 Dyspnea NIH 0.08
    D007251 Influenza, Human NIH 0.08
    D012120 Respiration Disorders NIH 0.06
    D012140 Respiratory Tract Diseases NIH 0.05
    D003141 Communicable Diseases NIH 0.02
    D007239 Infection NIH 0.01
    D045169 Severe Acute Respiratory Syndrome NIH 0.01
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (7)


    Name (Synonyms) Correlation
    HP:0002088 Abnormal lung morphology HPO 0.35
    HP:0002110 Bronchiectasis HPO 0.31
    HP:0002206 Pulmonary fibrosis HPO 0.28
    Name (Synonyms) Correlation
    HP:0006517 Intraalveolar phospholipid accumulation HPO 0.27
    HP:0001399 Hepatic failure HPO 0.27
    HP:0002090 Pneumonia HPO 0.13
    HP:0002098 Respiratory distress HPO 0.08

    Clinical Trials

    Navigate: Correlations   HPO

    There are 14 clinical trials


    1 The Benefits of Artificial Intelligence Algorithms (CNNs) for Discriminating Between COVID-19 and Influenza Pneumonitis in an Emergency Department Using Chest X-Ray Examinations

    This project aims to use artificial intelligence (image discrimination) algorithms, specifically convolutional neural networks (CNNs) for scanning chest radiographs in the emergency department (triage) in patients with suspected respiratory symptoms (fever, cough, myalgia) of coronavirus infection COVID 19. The objective is to create and validate a software solution that discriminates on the basis of the chest x-ray between Covid-19 pneumonitis and influenza

    NCT04313946
    Conditions
    1. COVID-19
    2. Pneumonia, Viral
    3. Influenza With Pneumonia
    4. Flu Symptom
    5. Flu Like Illness
    6. Pneumonia, Interstitial
    7. Pneumonia, Ventilator-Associated
    8. Pneumonia Atypical
    Interventions
    1. Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images
    MeSH:Pneumonia, Ventilator-Associated Influenza, Human Pneumonia, Viral Pneumonia Lung Diseases, Interstitial
    HPO:Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Number of participants with pneumonitis on Chest X-Ray and COVID 19 positive

    Measure: COVID-19 positive X-Rays

    Time: 6 months

    Description: Number of participants with pneumonitis on Chest X-Ray and COVID 19 negative

    Measure: COVID-19 negative X-Rays

    Time: 6 months
    2 Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection

    COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality. A short review includes: - Early December, 2019 - A pneumonia of unknown cause was detected in Wuhan, China, and was reported to the World Health Organization (WHO) Country Office. - January 30th, 2020 - The outbreak was declared a Public Health Emergency of International Concern. - February 7th, 2020 - 34-year-old Ophthalmologist who first identified a SARS-like coronavirus) dies from the same virus. - February 11th, 2020 - WHO announces a name for the new coronavirus disease: COVID-19. - February 19th, 2020 - The U.S. has its first outbreak in a Seattle nursing home which were complicated with loss of lives.. - March 11th, 2020 - WHO declares the virus a pandemic and in less than three months, from the time when this virus was first detected, the virus has spread across the entire planet with cases identified in every country including Greenland. - March 21st, 2020 - Emerging Infectious Disease estimates the risk for death in Wuhan reached values as high as 12% in the epicenter of the epidemic and ≈1% in other, more mildly affected areas. The elevated death risk estimates are probably associated with a breakdown of the healthcare system, indicating that enhanced public health interventions, including social distancing and movement restrictions, should be implemented to bring the COVID-19 epidemic under control." March 21st 2020 -Much of the United States is currently under some form of self- or mandatory quarantine as testing abilities ramp up.. March 24th, 2020 - Hot spots are evolving and identified, particularly in the areas of New York-New Jersey, Washington, and California. Immediate attention is turned to testing, diagnosis, epidemiological containment, clinical trials for drug testing started, and work on a long-term vaccine started. The recovering patients are presenting with mild to severe lung impairment as a result of the viral attack on the alveolar and lung tissues. Clinically significant impairment of pulmonary function appears to be a permanent finding as a direct result of the interstitial lung damage and inflammatory changes that accompanied. This Phase 0, first-in-kind for humans, is use of autologous, cellular stromal vascular fraction (cSVF) deployed intravenously to examine the anti-inflammatory and structural potential to improve the residual, permanent damaged alveolar tissues of the lungs.

    NCT04326036
    Conditions
    1. Pulmonary Alveolar Proteinosis
    2. COPD
    3. Idiopathic Pulmonary Fibrosis
    4. Viral Pneumonia
    5. Coronavirus Infection
    6. Interstitial Lung Disease
    Interventions
    1. Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)
    2. Device: Centricyte 1000
    3. Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution
    4. Drug: Liberase Enzyme (Roche)
    5. Drug: Sterile Normal Saline for Intravenous Use
    MeSH:Infection Communicable Diseases Coron Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Lung Diseases Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Lung Diseases, Interstitial Pulmonary Alveolar Proteinosis
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Intraalveolar phospholipid accumulation Pulmonary fibrosis

    Primary Outcomes

    Description: Reporting of Adverse Events or Severe Adverse Events Assessed by CTCAE v4.0

    Measure: Incidence of Treatment-Emergent Adverse Events

    Time: 1 month

    Secondary Outcomes

    Description: High Resolution Computerized Tomography of Lung (HRCT Lung) for Fluidda Analysis comparative at baseline and 3 and 6 months post-treatment comparative analytics

    Measure: Pulmonary Function Analysis

    Time: baseline, 3 Month, 6 months

    Description: Finger Pulse Oximetry taken before and after 6 minute walk on level ground, compare desaturation tendency

    Measure: Digital Oximetry

    Time: 3 months, 6 months
    3 TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia

    Immune-mediated lung injury plays a pivotal role in severe interstitial pnemumonia related to SARS-CoV2 infection. Tofacitinib, a JAK1/3-Inhibitor, could mitigate alveolar inflammation by blocking IL-6 signal. The aim of this prospective single cohort open study is to test the hypotesis that early administration of tofacitinib in patients with symptomatic pneumonia could reduce pulmonary flogosis, preventing function deterioration and the need of mechanical ventilation and/or admission in intensive care units.

    NCT04332042
    Conditions
    1. SARS-COv2 Related Interstitial Pneumonia
    Interventions
    1. Drug: Tofacitinib
    MeSH:Pneumonia Lung Diseases, Interstitial
    HPO:Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Rate of patients needing mechanical ventilation to maintain PaO2/FIO2>150 or, if PaO2 data not available, to maintain SO2>94% with FiO2 0,5.

    Measure: need of mechanical ventilation

    Time: day 14

    Secondary Outcomes

    Description: Rate of patients needing admission to the intensive care unit for oro-tracheal intubation and/or evidence of Multiple Organ Disfunction

    Measure: need of admission in intensive care unit

    Time: day 14

    Description: rate of patients dead

    Measure: death

    Time: day 28

    Description: rate and type of adverse events

    Measure: rate of adverse events

    Time: day 28
    4 Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19

    Currently there are no proven treatment option for COVID-19. Human convalescent plasma is an option for COVID-19 treatment and could be available from people who have recovered and can donate plasma.

    NCT04333251
    Conditions
    1. Pneumonia, Interstitial
    Interventions
    1. Biological: high-titer anti-Sars-CoV-2 plasma
    2. Other: oxygen therapy
    MeSH:Pneumonia Lung Diseases, Interstitial
    HPO:Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: reduction in oxygen and ventilation support

    Measure: reduction in oxygen and ventilation support

    Time: through study completion, an average of 4 weeks
    5 Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +

    The recent pandemic due to the SARS-CoV2 results in a pulmonary infection in major symptomatic patients. Because of the large number of patients and the risk of acute respiratory distress syndrome (which seems to occur in almost 5% of patients), there is a real challenge to improve physician ability to screen between patients those who will require specific surveillance and those who can be sent back home. The recent French official recommendation of the French radiology society prescribe that chest X-ray do not have any place in the COVID-19+ management whereas the WHO stipulate that ultrasound machines may be useful for these patients [1-2]. Moreover, scattered recent publications tend to stress the interest of quick ultrasound imaging for COVID-19 suspected patients for screening purpose [2-5]. The aim of this observational historico-prospective study is to assess the risk of severe clinical outcomes (admission in continuous care unit (USC), invasive respiratory assistance, death) in patients suspected or diagnosed COVID-19+ as a function of initial pulmonary ultrasound abnormalities. These clinical outcomes are assessed through phone calls at D5, D15, M1. The secondary objectives are: - Assessing the concordance between the severity of pulmonary lesions as detected by pulmonary ultrasound devices and the ones detected by CT-scanner, for patients who will undergo these two examinations. - Assessing the compared performances in detecting ultrasound pulmonary lesions for patients suspected or diagnosed COVID-19+, between an experimented operator and a newly trained operator.

    NCT04335019
    Conditions
    1. 2019-nCoV (COVID-19)
    2. Interstitial Pneumonia
    Interventions
    1. Other: Pulmonary ultrasound
    MeSH:Pneumonia Lung Diseases, Interstitial
    HPO:Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity There are few B lines at the lung bases Bi-lateralization of B lines, numerous diffuse and / or curtain sign Presence of signs of pulmonary consolidation, hepatization of the lung and air bronchogram)

    Measure: Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity

    Time: at day0

    Secondary Outcomes

    Measure: Assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by Cohen's kappa coefficient.

    Time: at day0

    Measure: Estimate in patients who had a CT-scan on D0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. CT-scan, by Cohen's kappa coefficient

    Time: at day0

    Measure: Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival

    Time: at day5

    Measure: Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival

    Time: at day15

    Measure: Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival

    Time: at day28
    6 Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

    Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells

    NCT04382547
    Conditions
    1. COVID
    2. Covid-19
    3. Coronavirus
    4. Pneumonia
    5. Pneumonia, Viral
    6. Pneumonia, Interstitial
    7. Sars-CoV2
    Interventions
    1. Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
    2. Other: Standard treatment according to the Clinical protocols
    MeSH:Pneumonia, Viral Pneumonia Lung Diseases, Interstitial
    HPO:Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Number of patients cured, assessed by PCR in addition to chest CT scan

    Measure: Number of cured patients

    Time: 3 weeks

    Secondary Outcomes

    Description: MSC infusion related adverse events assessed by blood count, liver and function tests

    Measure: Number of patients with treatment-related adverse events

    Time: 3 weeks
    7 TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia:a Multicenter Randomized Controlled Open Label Trial

    Multifocal interstitial pneumonia represents the most common cause of admission in intensive care units and death in SARS-CoV2 infections. In our Hospital, similarly to what reported in literature, up to 25% of admitted patients with pneumonitis requires mechanical ventilation or oro-tracheal intubation within 5-10 days. No established treatment is available for this condition. Preliminary evidence is accumulating about the efficacy of an aggressive treatment of the corona virus-induced inflammation and, in particular, investigators believe that blocking JAK1 is clinically rewarding in down-regulating IL-6 driven inflammation in patients with corona-virus infection. Thus, investigators designed a randomized controlled trial to test the hypothesis that adding Tofacitinib to the standard treatment in the early phase of COVID related pneumonitis could prevent the development of severe respiratory failure needing mechanical ventilation.

    NCT04390061
    Conditions
    1. Pneumonitis, Interstitial
    2. COVID-19
    Interventions
    1. Drug: Tofacitinib
    2. Drug: Hydroxychloroquine
    MeSH:Pneumonia Lung Diseases, Interstitial
    HPO:Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Rate of patients needing mechanical ventilation to maintain PaO2/FIO2>150

    Measure: Prevention of severe Respiratory Failure requiring mechanical ventilation

    Time: 14 days

    Secondary Outcomes

    Description: Rate of patients needing admission to the intensive care unit

    Measure: Prevention of need of ICU admission

    Time: 28 days

    Description: Rate of patients who die due to COVID-19 related conditions

    Measure: Prevention of COVID-19 related Deaths

    Time: 28 days

    Description: Role of some clinical and laboratory factors in predicting outcome (Age, sex, smoking status, Body Mass Index (BMI), Comorbidities (Diabetes, number of comorbidities), Respiratory Failure at admission defined as PaO2/FiO2<300, Extension of Ct-scan involvement, basal level of serum IL-6, vW-Factor, Thrombomodulin, KL-6, sACE2 and SP-D )

    Measure: Identification of predictors of outcome

    Time: 14 days

    Description: Rate of severe drug-related adverse events

    Measure: Incidence of Treatment-Emergent Adverse Events

    Time: 28 days
    8 Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection

    COVID-19, the infectious disease caused by the novel coronavirus SARS-CoV-2, currently poses a global economic, social, political and medical challenge. The virus originated in December 2019 in Wuhan, China, and has spread rapidly around the world. Currently, European countries, including Austria, are severely affected.The most common computed tomographic changes in acute lung injury include bilateral and subpleural milk glass opacity, consolidation in lower lobes, or both. In the intermediate phase of the infection (4-14 days after the onset of symptoms) a so-called "crazy paving" may occur. The most prominent radiological changes occur around day 10, followed by gradual resolution, which begins two weeks after the onset of symptoms. Given the phylogenetic relationship between SARS-CoV-1 and SARS-CoV-2, the similar clinical course in severe cases and overlapping CT patterns in the acute setting, persistent radiological and pulmonary functional changes in survivors are conceivable. It is also conceivable that a proportion of survivors will develop progressive ILD, either due to viral or ventilator-induced alveolar damage, or both. Here, the investigators intend to investigate COVID-19 survivors through clinical examinations, functional lung examinations, HR-CT scans, and by determining the "immunofibrotic" pattern in peripheral mononuclear cells (PBMCs) 1, 3, and 6 months after discharge.

    NCT04416100
    Conditions
    1. Covid-19
    2. Pulmonary Fibrosis
    Interventions
    1. Diagnostic Test: Pulmonary function tests
    2. Diagnostic Test: Imaging
    3. Biological: Blood sampling
    MeSH:Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pulmonary fibrosis

    Primary Outcomes

    Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 1 month after discharge or diagnosis of COVID-19 disease by the use of HR-CT.

    Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 1 month

    Time: 1 month

    Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 3 months after discharge or diagnosis of COVID-19 disease by the use of HR-CT

    Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 3 months

    Time: 3 months

    Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 6 months after discharge or diagnosis of COVID-19 disease by the use of HR-CT

    Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 6 months

    Time: 6 months
    9 SequelaeCov: a Prospective Study on Lung Damage Caused by SARS-CoV-2 Pneumonia

    Pneumonia is a recurrent element of COVID-19 infection, it is often associated with development of respiratory failure and patients frequently need various degrees of oxygen therapy up to non invasive ventilation (NIV-CPAP) and invasive mechanical ventilation (IMV). Main purpose of this study is to evaluate with non invasive clinical instruments (pletysmography, Diffusion lung capacity for carbon monoxide -DLCO-, six minute walking test and dyspnea scores) and radiological tools (chest X-ray and chest CT scan) the development of medium-to-long term pulmonary sequelae caused by SARS-CoV-2 pneumonia.

    NCT04435327
    Conditions
    1. COVID
    2. Pneumonia, Viral
    3. Barotrauma
    4. Interstitial Lung Disease
    5. Bronchiectasis Adult
    6. Emphysema
    MeSH:Pneumonia, Viral Pneumonia Lung Diseases Bronchiectasis Lung Diseases, Interstitial Emphysema Barotrauma
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Bronchiectasis Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Reduction below 80% of predicted values of DLCO

    Measure: Reduction of Diffusion of Lung CO (DLCO, single breath technique)

    Time: T1 at 6 months from discharge

    Description: Reduction below 80% of predicted values of DLCO

    Measure: Reduction of Diffusion of Lung CO (DLCO, single breath technique)

    Time: T2 at 12 months from discharge

    Secondary Outcomes

    Description: reduction in maximum distance walked

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T1 at 6 months from discharge

    Description: reduction in maximum distance walked

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T2 at 12 months from discharge

    Description: reduction in oxygen saturation nadir

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T1 at 6 months from discharge

    Description: reduction in oxygen saturation nadir

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Vital Capacity (VC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Vital Capacity (VC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Vital Capacity (VC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Vital Capacity (VC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L%)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Total Lung Capacity (TLC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Total Lung Capacity (TLC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Total Lung Capacity (TLC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Total Lung Capacity (TLC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Residual Volume (RV,%)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Residual Volume (RV, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Residual Volume (RV, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Residual Volume (RV, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (absolute value)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (%)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (absolute value)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (%)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Motley Index (VR/CPT)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Motley Index (VR/CPT)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Tiffeneau Index (IT)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Tiffeneau Index (IT)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of PaO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T1 at 6 months from discharge

    Description: reduction of PaO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T2 at 12 months from discharge

    Description: alteration of PaCO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T1 at 6 months from discharge

    Description: alteration of PaCO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T2 at 12 months from discharge

    Description: Modified Medical Research Council - mMRC > 0 (minimum 0, maximum 4; higher score means worse outcome)

    Measure: Abnormal Dyspnea Score

    Time: T1 at 6 months from discharge

    Description: Modified Medical Research Council - mMRC > 0(minimum 0, maximum 4; higher score means worse outcome)

    Measure: Abnormal Dyspnea Score

    Time: T2 at 12 months from discharge

    Description: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Measure: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Time: T1 at 6 months from discharge

    Description: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Measure: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Time: T2 at 12 months from discharge

    Description: Presence and extension of radiological alterations at chest X-ray

    Measure: Presence and extension of radiological alterations at chest X-ray

    Time: T1 at 6 months from discharge

    Description: Presence and extension of radiological alterations at chest CT scan

    Measure: Presence and extension of radiological alterations at chest CT scan

    Time: T2 at 12 months from discharge
    10 Identification of Predictors for the Evolution of COVID-19 Related Interstitial Pneumonia by Transcriptomic and Seroproteomic Techniques

    The investigating group aims at performing an observational, prospective study that involves the evaluation of circulating biomarkers predictive of clinical evolution in patients suffering from COVID-19 disease. In particular, the aim will be to verify whether there are transcripts or cytokines / chemokines in peripheral blood, modulated differently in patients with COVID-19, distinguished on the basis of the evolution towards more severe clinical pictures that require patient intubation or that show signs of cardiovascular damage. The study will be based on the transcriptional analysis of the entire genome and serum protein to evaluate the expression of a broad spectrum of cytokines and chemokines. Genome analysis will allow the genotype to be correlated to the identified gene expression profiles.

    NCT04441502
    Conditions
    1. Covid19
    2. Interstitial Pneumonia
    MeSH:Pneumonia Lung Diseases, Interstitial
    HPO:Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Identify circulating transcripts (coding and non-coding for proteins) or cytokines and chemokines which, alone or in combination (COVID19_signature), are predictive of adverse events (death, endotracheal intubation) and the prognostic capacity of COVID19_signature in the prediction of adverse events in additional to the use of standard clinical parameters

    Measure: Circulating markers for COVID-19 signature

    Time: From ICU/ward admission for 8 weeks follow/up

    Secondary Outcomes

    Description: Evaluate the association of COVID19_signature with adverse cardiovascular events. Adverse cardiovascular events are defined: death from cardiovascular causes, acute coronary syndrome, troponin T levels greater than the ninety-ninth percentile of the upper reference limit, stroke, cardiac arrhythmias, development of heart failure, venous thromboembolism

    Measure: COVID-19 signature and adverse cardiovascular events

    Time: From ICU/ward admission for 8 weeks follow/up

    Description: Evaluate, in a subset of 20 patients, the characteristics of the coagulation pattern with specific tests for thrombin generation and fibrinolysis.

    Measure: COVID-19 related coagulation pattern

    Time: From ICU/ward admission for 8 weeks follow/up
    11 Clinical, Laboratory and Imaging Comparison Between COVID-19 Pneumonia Confirmed by PCR Detection on Nasopharyngeal Swab and Negative Swab Pneumonia

    In the late 2019 a new Coronavirus was identified as the cause of a group of atypical interstitial pneumonia cases in Wuhan, a city in the Chinese province of Hubei. In February 2020, the World Health Organization designated COVID-19 disease, which stands for Coronavirus 2019 disease. Following the progressive spread of the infection in other countries of the world, WHO declared the Pandemic on 11 March 2020. Italy was the first European country involved in the spread of the infection and among those with the highest number of victims. The Coronavirus responsible for COVID-19 has, as its main target organ, the respiratory system, being able to determine a serious acute respiratory syndrome similar to that of the cases found during the SARS epidemic of 2003: hence the name of the virus as SARS-CoV-2. The diagnosis of SARS-COV-2 infection is made by direct detection by PCR of viral RNA on different biological materials from patients with suspicious symptoms, and the first level diagnostic test is generally the nasopharyngeal swab. However, even if the specificity of the nasopharyngeal swab is high, its sensitivity can be affected by technical causes (sampling mode), as well as by intrinsic factors related to the method. The purpose of the study is to identify the clinical, laboratory and imaging characteristic which are similar or which can differentiate the hospitalized patients affected by COVID-19 pneumonia (with positive PCR on naso-pharyngeal swab) and patients with pneumonia with negative PCR for COVID-19. To do this, the investigators will compare the clinical, laboratory and imaging characteristics between interstitial pneumonia secondary to SARS-COV-2 infection, confirmed by molecular biology investigations (viral RNA research by PCR on nasopharyngeal swab) and cases of interstitial pneumonia negative to the nasopharyngeal swab.

    NCT04507893
    Conditions
    1. Covid19
    2. Interstitial Pneumonia
    Interventions
    1. Other: Clinical, laboratory and imaging characteristics of pneumonia
    MeSH:Pneumonia Lung Diseases, Interstitial
    HPO:Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Accuracy of severity of respiratory insufficiency - evaluated as need of three step "nasal oxygen, oxygen mask, invasive ventilation" - in differentiate COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as "COVID-19 patients" and "COVID-19 negative controls"

    Measure: Evaluation of the clinical characteristics of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as "COVID-19 patients" and "COVID-19 negative controls".

    Time: 75 Days

    Description: Accuracy of the association of 3 haemato-chemical abnormalities (lymphopenia + increased serum transaminases + increased serum LDH) in differentiate COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as "COVID-19 patients" and "COVID-19 negative controls".

    Measure: Evaluation of the laboratory characteristics of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as "COVID-19 patients" and "COVID-19 negative controls".

    Time: 75 Days

    Description: Accuracy of thorax CT scan in differentiate COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as "COVID-19 patients" and "COVID-19 negative controls".

    Measure: Evaluation of the imaging characteristics of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as "COVID-19 patients" and "COVID-19 negative controls".

    Time: 75 Days

    Secondary Outcomes

    Description: Evaluation of mortality in "COVID-19 patients" and "COVID-19 negative controls", hospitalized in the study period.

    Measure: Evaluation of mortality of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as "COVID-19 patients" and "COVID-19 negative controls".

    Time: 75 Days

    Description: Evaluation of clinical severity in "COVID-19 patients" and "COVID-19 negative controls", hospitalized in the study period.

    Measure: Evaluation of clinical severity of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as "COVID-19 patients" and "COVID-19 negative controls".

    Time: 75 Days

    Description: Evaluation of hospital stay length in "COVID-19 patients" and "COVID-19 negative controls", hospitalized in the study period.

    Measure: Evaluation of hospital stay length of patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay as "COVID-19 patients" and "COVID-19 negative controls".

    Time: 75 Days
    12 A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial

    A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)

    NCT04574050
    Conditions
    1. Cancer
    2. COPD
    3. Asthma
    4. Bronchiectasis Adult
    5. Interstitial Lung Disease
    6. Cystic Fibrosis
    7. Chronic Heart Failure
    8. Sickle Cell Disease
    9. Renal Failure
    10. Liver Failure
    11. Post COVID-19
    12. Dyspnea
    Interventions
    1. Other: SELF-BREATHE
    MeSH:Cystic Fibrosis Liver Failure Lung Diseases Dyspnea Bronchiectasis Lung Diseases, Interstitial Anemia, Sickle Cell
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Bronchiectasis Dyspnea Hepatic failure Interstitial pneumonitis Respiratory distress

    Primary Outcomes

    Description: The number of patients recruited into this study over a 12-month period

    Measure: Feasibility: the number of patients recruited into this study over a 12-month period

    Time: 12 months
    13 Early Nintedanib Deployment in COVID-19 Interstitial Fibrosis

    This is a collaborative study between Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim Pharmaceuticals to determine the effect of Nintedanib on slowing the rate of lung fibrosis in patients who have been diagnosed with COVID-19, and have ongoing lung injury more than 4 weeks out from their diagnosis.

    NCT04619680
    Conditions
    1. Pulmonary Fibrosis
    2. Interstitial Lung Disease
    3. Respiratory Disease
    Interventions
    1. Drug: Nintedanib
    2. Drug: Placebo
    MeSH:Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial Respiration Disorders Respiratory Tract Diseases Fibrosis
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pulmonary fibrosis

    Primary Outcomes

    Description: Change in Forced Vital Capacity (FVC) at 180 days as compared to baseline. Forced vital capacity (FVC) is the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible, as measured by spirometry.

    Measure: Change in Forced Vital Capacity (FVC)

    Time: Baseline and 180 days

    Secondary Outcomes

    Description: Death within 90 days and 180 days from enrollment due to a respiratory cause

    Measure: Number of deaths due to respiratory cause

    Time: within 90-180 days

    Description: Quantitative Change in chest CT visual score graded by blinded chest radiologists. Data driven texture analysis (DTA) is a patented deep learning method to quantify lung fibrosis. DTA score is reported in percentage ranging from 0% to 100%. A minimally clinical important difference when comparing CT scans from the same subject is 4%. A higher percentage suggests worsening lung injury.

    Measure: Chest CT visual score

    Time: 180 days

    Description: The Saint George's Respiratory Questionnaire (SGRQ) is a self-reported disease-specific, health-related quality of life (QOL) questionnaire. 50-item instrument. Scores range from 0 to 100, with higher scores indicating more limitations.

    Measure: St. George's Respiratory Questionnaire (SGRQ)

    Time: Day 90

    Description: The Saint George's Respiratory Questionnaire (SGRQ) is a self-reported disease-specific, health-related quality of life (QOL) questionnaire. 50-item instrument. Scores range from 0 to 100, with higher scores indicating more limitations.

    Measure: St. George's Respiratory Questionnaire (SGRQ)

    Time: Day 180

    Description: The King's Brief Interstitial Lung Disease (KBILD) questionnaire is a self-administered, ILD-specific measure of health-related quality of life, comprising 15 items with three domains (Psychological (KBILD-P), Breathlessness and activities (KBILD-B), and Chest symptoms (KBILD-C)) combined in a total score (KBILD-T). The KBILD domain and total score ranges are 0-100; 100 represents best health status.

    Measure: King's Brief Interstitial Lung Disease (KBILD)

    Time: Day 90

    Description: The King's Brief Interstitial Lung Disease (KBILD) questionnaire is a self-administered, ILD-specific measure of health-related quality of life, comprising 15 items with three domains (Psychological (KBILD-P), Breathlessness and activities (KBILD-B), and Chest symptoms (KBILD-C)) combined in a total score (KBILD-T). The KBILD domain and total score ranges are 0-100; 100 represents best health status.

    Measure: King's Brief ILD (KBILD)

    Time: Day 180

    Description: The LCQ is a 19 item questionnaire that assesses cough-related QOL. It has 3 domains (physical, psychological and social). The domain scores range from 1-7 and total score range is 3-21 with a higher score indicating a better quality of life.

    Measure: Leicester Cough Questionnaire (LCQ)

    Time: Day 90

    Description: The LCQ is a 19 item questionnaire that assesses cough-related QOL. It has 3 domains (physical, psychological and social). The domain scores range from 1-7 and total score range is 3-21 with a higher score indicating a better quality of life.

    Measure: Leicester Cough Questionnaire

    Time: Day 180

    Description: The (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status. Scores range from 0 - 100, with higher scores indicating less disability.

    Measure: Short Form (SF) 36 Health Survey

    Time: Day 90

    Description: The (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status. Scores range from 0 - 100, with higher scores indicating less disability.

    Measure: SF 36 Health Survey

    Time: Day 180

    Description: Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression. 14-items scale with responses scored from 0-3, scores for each subscale from 0 (normal) to 21 (severe symptoms). Scores for the entire scale is 0 to 42, with higher score indicating more distress.

    Measure: Hospital Anxiety and Depression Scale (HADS)

    Time: Day 90

    Description: Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression. 14-items scale with responses scored from 0-3, scores for each subscale from 0 (normal) to 21 (severe symptoms). Scores for the entire scale is 0 to 42, with higher score indicating more distress.

    Measure: Hospital Anxiety and Depression Scale (HADS)

    Time: Day 180

    Description: Number of participants with Increase in liver transaminases

    Measure: Number of participants with Increase in liver transaminases (AST and ALT) > 3 times the upper limit of normal

    Time: day 90

    Description: Number of participants with Increase in liver transaminases

    Measure: Number of participants with Increase in liver transaminases (AST and ALT) > 3 times the upper limit of normal

    Time: day 180

    Description: Number of participants with Thrombotic events: venous or arterial thrombosis

    Measure: Number of participants with Thrombotic events

    Time: day 90

    Description: Number of participants with Thrombotic events: venous or arterial thrombosis

    Measure: Number of participants with Thrombotic events

    Time: day 180

    Description: Number of participants with 10% weight loss

    Measure: Number of participants with 10% weight loss over 90 days

    Time: day 90

    Description: Number of participants with 10% weight loss

    Measure: Number of participants with 10% weight loss over 90 days

    Time: day 180

    Description: Number of participants with Nausea/emesis/diarrhea not responsive to anti-emetics and anti-motility agents

    Measure: Number of participants with GI events

    Time: day 90

    Description: Number of participants with Nausea/emesis/diarrhea not responsive to anti-emetics and anti-motility agents

    Measure: Number of participants with GI events

    Time: day 180
    14 Multicenter, Open-label Prospective Cohort Study of the Efficacy and Safety of the Inclusion of Longidaze in the Prevention and Treatment of Post-inflammatory Pulmonary Fibrosis and Interstitial Lung Diseases Caused by COVID-19.

    A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.

    NCT04645368
    Conditions
    1. Fibroses, Pulmonary
    Interventions
    1. Drug: bovhyaluronidase azoxymer
    MeSH:Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial Fibrosis
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pulmonary fibrosis

    Primary Outcomes

    Description: The severity of pulmonary tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group according to the results of a blinded central laboratory

    Measure: The severity of lung tissue lesions with fibrosis and interstitial changes on day 75

    Time: Day 0, Day 75

    Secondary Outcomes

    Description: The severity of lung tissue damage by fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 6 months in relation to the baseline values of the indicator in patients of the Longidaze® group in comparison with the the dynamic observation group (according to the results of a blinded central laboratory)

    Measure: The severity of lung tissue damage by fibrosis and interstitial changes (%) on day 180

    Time: Day 0, Day 180

    Description: The severity of lung tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group (according to the results of the local laboratory)

    Measure: The severity of lung tissue lesions with fibrosis and interstitial changes (%) on day 75 and day 180

    Time: Day 0, Day 75, Day 180

    Description: The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) based on the high-resolution computed tomography images analyzed by the Botkin.AI program (artificial intelligence) and then verified by a specialist after 2.5 months and 6 months from the beginning of observation in relation to the baseline values of indicators in patients of the Longidaze® group in comparison with the dynamic observation group

    Measure: The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) images analyzed by the Botkin.AI program (artificial intelligence)

    Time: Day 75, Day 180

    Description: Change in forced vital capacity FVC (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group

    Measure: Change in forced vital capacity (FVC)

    Time: Day 0, Day 75, Day 180

    Description: Change in the diffusion capacity of the lungs (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group

    Measure: Change in the diffusion capacity of the lungs

    Time: Day 0, Day 75, Day 180

    Description: Change in the degree of dyspnea on the MMRC scale from baseline after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group. MMRC scale (Modified Medical Research Council scale) 0 - no - Dyspnea does not bother, except for very intense exercise - mild - Shortness of breath bothers with brisk walking or climbing a small elevation - moderate to severe - Shortness of breath results in slower walking compared to other people of the same age, or need to stop while walking at normal pace on a level surface - Severe - Shortness of breath makes you stop when walking about 100 m or after a few minutes of walking on a flat surface - very severe - Shortness of breath makes it impossible to leave the house or appears when dressing and undressing

    Measure: Change in the degree of dyspnea on the MMRC scale

    Time: Day 0, Day 75, Day 180

    Description: Changes in SpO2 of capillary blood relative to the initial value after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Changes in capillary blood oxygen saturation (SpO2)

    Time: Day 0, Day 75, Day 180

    Description: Changes in the covered footage in the 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Changes in the covered footage in the 6-minute walk test

    Time: Day 0, Day 75, Day 180

    Description: Changes in capillary blood saturation (SpO2) after a 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Changes in capillary blood saturation (SpO2) after a 6-minute walk test

    Time: Day 0, Day 75, Day 180

    Description: Change in the residual volume of the lungs after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Change in the residual volume of the lungs

    Time: Day 0, Day 75

    Description: Change in the total lung capacity after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Change in the total lung capacity

    Time: Day 0, Day 75

    Description: Change in inspiratory capacity after 2.5 months in patients of the Longidaze® group compared with dynamic observation group

    Measure: Change in inspiratory capacity

    Time: Day 75

    HPO Nodes


    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook